Keywords: Renal cancer, GlaxoSmithKline, Pfizer, Novartis, Bayer
Changes predicted in renal cell carcinoma market leaders
Article | 15 September 2009
Following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (pazopanib; formerly Armala) will garner sales of $640 million by 2018 and will ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
